Insights into the molecular basis of action of the AT1 antagonist losartan using a combined NMR spectroscopy and computational approach

Biochimica et Biophysica Acta - Biomembranes

Volumn 1838, Issue 3, 2014, Pages 1031-1046

  Zervou, Maria ^a   Cournia, Zoe ^b   Potamitis, Constantinos ^a   Patargias, George ^b   Durdagi, Serdar ^a   Grdadolnik, Simona Golic ^c,d   Mavromoustakos, Thomas ^a,e  

^a INSTITUTE OF BIOLOGY   (Greece)

^b BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^c NATIONAL INSTITUTE OF CHEMISTRY   (Slovenia)

^d EN FIST CENTRE OF EXCELLENCE   (Slovenia)

^e UNIVERSITY OF ATHENS   (Greece)

Author keywords

Losartan; Molecular dynamics in micelles; NMR (DOSY, NOESY ROESY); SDS micelles; Spin labels

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; DIMETHYL SULFOXIDE; DIPALMITOYLPHOSPHATIDYLCHOLINE; DODECYL SULFATE SODIUM; LOSARTAN; WATER;

ARTICLE; BILAYER MEMBRANE; CONTROLLED STUDY; DRUG BINDING; DRUG CONFORMATION; MEMBRANE BINDING; MICELLE; MOLECULAR DYNAMICS; MOLECULAR MODEL; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHARMACOPHORE; PRIORITY JOURNAL;

LOSARTAN; MOLECULAR DYNAMICS IN MICELLES; MOLECULAR DYNAMICS IN PHOSPHOLIPID BILAYERS WITH EMBEDDED AT(1) RECEPTOR; NMR (DOSY, NOESY/ROESY); SDS MICELLES; SPIN LABELS;

CALORIMETRY, DIFFERENTIAL SCANNING; CATALYTIC DOMAIN; CELL MEMBRANE; COMPUTATIONAL BIOLOGY; HUMANS; LIPID BILAYERS; LOSARTAN; MAGNETIC RESONANCE SPECTROSCOPY; MICELLES; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; PROTEIN CONFORMATION; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, G-PROTEIN-COUPLED; SPIN LABELS;

EID: 84892713481     PISSN: 00052736     EISSN: 18792642     Source Type: Journal    
DOI: 10.1016/j.bbamem.2013.12.012     Document Type: Article

References (64)

1. S.Y. Yang Pharmacophore modeling and applications in drug discovery: challenges and recent advances Drug Discov. Today 15 2010 444 450
2. H. Kubinyi Success stories of computer-aided design S. Ekins, Computer Applications in Pharmaceutical Research and Development 2006 John Wiley & Sons, Inc. Hoboken, NJ, USA
3. T. Mavromoustakos, M. Zervou, P. Zoumpoulakis, I. Kyrikou, N.P. Benetis, L. Polevaya, P. Roumelioti, N. Giatas, A. Zoga, P.M. Minakakis, A. Kolocouris, D. Vlahakos, S.G. Grdadolnik, and J. Matsoukas Conformation and bioactivity. Design and discovery of novel antihypertensive drugs Curr. Top. Med. Chem. 4 2004 385 401 (Pubitemid 38854830)
4. B. Musafia, and H. Senderowitz Biasing conformational ensembles towards bioactive-like conformers for ligand-based drug design Expert Opin. Drug Discovery 5 2010 943 959
5. R.R. Wexler, W.J. Greenlee, J.D. Irvin, M.R. Goldberg, K. Prendergast, R.D. Smith, and P.B.M.W.M. Timmermans Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy J. Med. Chem. 39 1996 625 656 (Pubitemid 26069685)
6. K. Dickstein, P. Timmermans, and R. Segal Losartan: a selective angiotensin II type 1 (AT1) receptor antagonist for the treatment of heart failure Expert Opin. Investig. Drugs 7 1998 1897 1914 (Pubitemid 28505095)
7. T. Mavromoustakos, A. Kolocouris, M. Zervou, P. Roumelioti, J. Matsoukas, and R. Weisemann An effort to understand the molecular basis of hypertension through the study of conformational analysis of Losartan and Sarmesin using a combination of nuclear magnetic resonance spectroscopy and theoretical calculations J. Med. Chem. 42 1999 1714 1722 (Pubitemid 29244965)
8. X.R. Hu, Y.W. Wang, and J.M. Gu Losartan potassium 3.5-hydrate, a new crystalline form Acta Crystallogr. E 61 2005 M1686 M1688
9. D. Fernandez, D. Vega, J.A. Ellena, and G. Echeverria Losartan potassium, a non-peptide agent for the treatment of arterial hypertension Acta Crystallogr. C 58 2002 m418 m420
10. L. Tessler, and I. Goldberg Losartan, an antihypertensive drug Acta Crystallogr. E 60 2004 o1830 o1832
11. P. Zoumpoulakis, I. Daliani, M. Zervou, I. Kyrikou, E. Siapi, G. Lamprinidis, E. Mikros, and T. Mavromoustakos Losartan's molecular basis of interaction with membranes and AT1 receptor Chem. Phys. Lipids 125 2003 13 25 (Pubitemid 37414802)
12. 31P NMR broadline simulation methodology for studying the interactions of antihypertensive AT1 antagonist losartan with phospholipid bilayers Biophys. J. 96 2009 2227 2236
13. T. Mavromoustakos, S. Durdagi, C. Koukoulitsa, M. Simcic, M.G. Papadopoulos, M. Hodoscek, and S.G. Grdadolnik Strategies in the rational drug design Curr. Med. Chem. 18 2011 2517 2530
14. E. Theodoropoulou, and D. Marsh Interactions of angiotensin II non-peptide AT(1) antagonist losartan with phospholipid membranes studied by combined use of differential scanning calorimetry and electron spin resonance spectroscopy Biochim. Biophys. Acta 1461 1999 135 146 (Pubitemid 30077469)
15. M.A. Bhuiyan, M. Ishiguro, M. Hossain, T. Nakamura, M. Ozaki, S. Miura, and T. Nagatomo Binding sites of valsartan, candesartan and losartan with angiotensin II receptor 1 subtype by molecular modeling Life Sci. 85 2009 136 140
16. T. Tuccinardi, V. Calderone, S. Rapposelli, and A. Martinelli Proposal of a new binding orientation for non-peptide AT1 antagonists: homology modeling, docking and three-dimensional quantitative structure-activity relationship analysis J. Med. Chem. 49 2006 4305 4316 (Pubitemid 44036674)
17. C. Baleanu-Gogonea, and S. Karnik Model of the whole rat AT1 receptor and the ligand-binding site J. Mol. Model. 12 2006 325 337 (Pubitemid 43337202)
18. H. Unal, R. Jagannathan, A. Bhatnagar, K. Tirupula, R. Desnoyer, and S.S. Karnik Long range effect of mutations on specific conformational changes in the extracellular loop 2 of angiotensin II type 1 receptor J. Biol. Chem. 288 2013 540 551
19. S. Topiol, and M. Sabio X-ray structure breakthroughs in the GPCR transmembrane region Biochem. Pharmacol. 78 2009 11 20
20. M. Congreve, C.J. Langmead, J.S. Mason, and F.H. Marshall Progress in structure based drug design for G protein-coupled receptors J. Med. Chem. 54 2011 4283 4311
21. M.T. Matsoukas, C. Potamitis, P. Plotas, M.E. Androutsou, G. Agelis, J. Matsoukas, and P. Zoumpoulakis Insights into AT1 receptor activation through AngII binding studies J. Chem. Inf. Model 53 2013 2798 2811
22. M.T. Matsoukas, A. Cordomi, S. Rios, L. Pardo, and T. Tselios Ligand binding determinants for Angiotensin II Type 1 receptor from computer simulations J. Chem. Inf. Model 53 2013 2874 2883
23. S. Nagar, and K. Korzekwa Commentary: nonspecific protein binding versus membrane partitioning: it is not just semantics Drug Metab. Dispos. 40 2012 1649 1652
24. G. Vauquelin, and A. Packeu Ligands, their receptors and. plasma membranes Mol. Cell. Endocrinol. 311 2009 1 10
25. A.M. Seddon, D. Casey, R.V. Law, A. Gee, R.H. Templer, and O. Ces Drug interactions with lipid membranes Chem. Soc. Rev. 38 2009 2509 2519
26. Y. Xu, V.E. Yushmanov, and P. Tang NMR studies of drug interaction with membranes and membrane-associated proteins Biosci. Rep. 22 2002 175 196 (Pubitemid 35222731)
27. D.E. Warschawski, A.A. Arnold, M. Beaugrand, A. Gravel, E. Chartrand, and I. Marcotte Choosing membrane mimetics for NMR structural studies of transmembrane proteins Biochim. Biophys. Acta 1808 2011 1957 1974
28. D.L. Daleke Regulation of transbilayer plasma membrane phospholipid asymmetry J. Lipid Res. 44 2003 233 242 (Pubitemid 37303867)
29. T.R. Oliveira, M.T. Lamy, U.M. De Paula, L.L. Guimaraes, M.S. Toledo, H.K. Takahashi, A.H. Straus, C.J. Lindsey, and T.B. Paiva Structural properties of lipid reconstructs and lipid composition of normotensive and hypertensive rat vascular smooth muscle cell membranes Braz. J. Med. Biol. Res. 42 2009 844 885
30. P. Sokkar, S. Mohandass, and M. Ramachandran Multiple templates-based homology modeling enhances structure quality of AT1 receptor: validation by molecular dynamics and antagonist docking J. Mol. Model. 17 2011 1565 1577
31. C. Fotakis, D. Christodouleas, P. Zoumpoulakis, E. Kritsi, N.P. Benetis, T. Mavromoustakos, H. Reis, A. Gili, M.G. Papadopoulos, and M. Zervou Comparative biophysical studies of sartan class drug molecules losartan and candesartan (CV-11974) with membrane bilayers J. Phys. Chem. B 115 2011 6180 6192
32. F. Li, L. Wang, N. Xiao, M. Yang, L. Jiang, and M. Liu Dominant conformation of valsartan in sodium dodecyl sulfate micelle environment J. Phys. Chem. B 114 2010 2719 2727
33. C. Cao, J. Mao, F. Li, M. Yang, H. He, L. Jiang, and M. Liu Understanding the interaction between valsartan and detergents by NMR techniques and molecular dynamics simulation J. Phys. Chem. B 116 2012 7470 7478
34. A.D. Mackerell Molecular-dynamics simulation analysis of a sodium dodecyl-sulfate micelle in aqueous-solution - Decreased fluidity of the micelle hydrocarbon interior J. Phys. Chem. 99 1995 1846 1855
35. http://moose.bio.ucalgary.ca/index.php?page=Structures-and-Topologies (Access date: 18/11/2013)
36. C. Fotakis, S. Gega, E. Siapi, C. Potamitis, K. Viras, P. Moutevelis-Minakakis, C.G. Kokotos, S. Durdagi, S.G. Grdadolnik, B. Sartori, M. Rappolt, and T. Mavromoustakos Interactions at the bilayer interface and receptor site induced by the novel synthetic pyrrolidinone analog MMK3 BBA-Biomembr. 1798 2010 422 432
37. M. Lindberg, J. Jarvet, U. Langel, and A. Graslund Secondary structure and position of the cell-penetrating peptide transportan in SDS micelles as determined by NMR Biochemistry 40 2001 3141 3149 (Pubitemid 32205358)
38. S.G. Grdadolnik, and D.F. Mierke Vancomycin: interactions with a model cell membrane Biopolymers 42 1997 627 632
39. C. Griesinger, and R.R. Ernst Frequency offset effects and their elimination in NMR rotating-frame cross-relaxation spectroscopy J. Magn. Reson. 75 1987 261 271
40. MacroModel, version 9.9 2012 Schrödinger, LLC New York, NY
41. A. Chaudhuri, S. Haldar, and A. Chattopadhyay Organization and dynamics in micellar structural transition monitored by pyrene fluorescence Biochem. Biophys. Res. Commun. 390 2009 728 732
42. E.L. Doyle, C.A. Hunter, H.C. Phillips, S.J. Webb, and N.H. Williams Cooperative binding at lipid bilayer membrane surfaces J. Am. Chem. Soc. 125 2003 4593 4599 (Pubitemid 36418706)
43. Desmond Molecular Dynamics System, version 3.1 2012 D. E. Shaw Research New York, NY (Maestro-Desmond Interoperability Tools, version 3.1, Schrödinger, New York, NY, 2012)
44. M. Tuckerman, B.J. Berne, and G.J. Martyna Reversible multiple time scale molecular-dynamics J. Chem. Phys. 97 1992 1990 2001
45. H.J.C. Berendsen, J.P.M. Postma, W.F. Vangunsteren, A. Dinola, and J.R. Haak Molecular-dynamics with coupling to an external bath J. Chem. Phys. 81 1984 3684 3690
46. U. Essmann, L. Perera, M.L. Berkowitz, T. Darden, H. Lee, and L.G. Pedersen A smooth particle mesh Ewald method J. Chem. Phys. 103 1995 8577 8593
47. Maestro, version 9.3 2012 Schrödinger, LLC New York, NY
48. The PyMOL Molecular Graphics System, Version 1.5.0.4 Schrödinger, LLC.
49. H.J.C. Berendsen, D. van der Spoel, and R. van Drunen GROMACS: a message-passing parallel molecular dynamics implementation Comput. Phys. Commun. 91 1995 43 56
50. C. Oostenbrink, A. Villa, A.E. Mark, and W.F. van Gunsteren A biomolecular force field based on the free enthalpy of hydration and solvation: the GROMOS force-field parameter sets 53A5 and 53A6 J. Comput. Chem. 25 2004 1656 1676
51. J.F. Nagle, R.T. Zhang, S. TristramNagle, W.J. Sun, H.I. Petrache, and R.M. Suter X-ray structure determination of fully hydrated L(alpha) phase dipalmitoylphosphatidylcholine bilayers Biophys. J. 70 1996 1419 1431
52. M.G. Wolf, M. Hoefling, C. Aponte-Santamaria, H. Grubmuller, and G. Groenhof g-membed: efficient insertion of a membrane protein into an equilibrated lipid bilayer with minimal perturbation J. Comput. Chem. 31 2010 2169 2174
53. http://davapc1.bioch.dundee.ac.uk/cgi-bin/prodrg/ (Access date: 18/11/2013)
54. J.A. Lemkul, W.J. Allen, and D.R. Bevan Practical considerations for building GROMOS-compatible small-molecule topologies J. Chem. Inf. Model. 50 2010 2221 2235
55. M. Valiev, E.J. Bylaska, N. Govind, K. Kowalski, T.P. Straatsma, H.J.J. van Dam, D. Wang, J. Nieplocha, E. Apra, T.L. Windus, and W.A. de Jong NWChem: a comprehensive and scalable open-source solution for large scale molecular simulations Comput. Phys. Commun. 181 2010
56. http://www.nwchem-sw.org/ (Access date: 18/11/2013)
57. J. Rebek Jr. Contortions of encapsulated alkyl groups Chem. Commun. 2007 2777 2789 (Pubitemid 47035544)
58. 1H NMR spectroscopic investigations on the conformation of amphiphilic aromatic amino acid derivatives in solution: effect of chemical architecture of amphiphiles and polarity of solvent medium J. Phys. Chem. B 114 2010 13691 13702
59. H.W. Van Den Hooven, C.A. Spronk, M. Van De Kamp, R.N. Konings, C.W. Hilbers, and F.J. Van De Van Surface location and orientation of the lantibiotic nisin bound to membrane-mimicking micelles of dodecylphosphocholine and of sodium dodecylsulphate Eur. J. Biochem. 235 1996 394 403 (Pubitemid 26045455)
60. A. Hodzic, P. Zoumpoulakis, G. Pabst, T. Mavromoustakos, and M. Rappolt Losartan's affinity to fluid bilayers modulates lipid-cholesterol interactions Phys. Chem. Chem. Phys. 14 2012 4780 4788
61. G. Vauquelin, and S.J. Charlton Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action Br. J. Pharmacol. 161 2010 488 508
62. C. Fotakis, G. Megariotis, D. Christodouleas, E. Kritsi, P. Zoumpoulakis, D. Ntountaniotis, M. Zervou, C. Potamitis, A. Hodzic, G. Pabst, M. Rappolt, G. Mali, J. Baldus, C. Glaubitz, M.G. Papadopoulos, A. Afantitis, G. Melagraki, and T. Mavromoustakos Comparative study of the AT(1) receptor prodrug antagonist candesartan cilexetil with other sartans on the interactions with membrane bilayers Biochim. Biophys. Acta 1818 2012 3107 3120
63. C. Potamitis, M. Zervou, V. Katsiaras, P. Zoumpoulakis, S. Durdagi, M.G. Papadopoulos, J.M. Hayes, S.G. Grdadolnik, I. Kyrikou, D. Argyropoulos, G. Vatougia, and T. Mavromoustakos Antihypertensive drug valsartan in solution and at the AT(1) receptor: conformational analysis, dynamic NMR spectroscopy Silico docking, and molecular dynamics simulations J Chem Inf Model 49 2009 726 739
64. J.M. Saavedra Angiotensin II AT(1) receptor blockers as treatments for inflammatory brain disorders Clin. Sci. 123 2012 567 590